Eisai Co., Ltd.: Carcinoma trials

The registry lists 22 Carcinoma studies with Eisai Co., Ltd. as lead sponsor. 0 are open to participants now and 12 have results posted.

Phase 1 8Phase 2 9Phase 3 2Phase 4 1No phase 6(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Trial to Evaluate Safety and Efficacy of Treatment of Physician Choice (TPC) Following First-Line Treatment of Lenvatinib in Subjects With Unresectable Hepatocellular Carcinoma (uHCC)TerminatedNCT03433703Phase 2Results posted
• A Study of Lenvatinib Plus Nivolumab in Participants With Hepatocellular CarcinomaCompletedNCT03418922Phase 1Results posted
• Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell CarcinomaCompletedNCT03173560Phase 2Results posted
• A Trial of Lenvatinib Plus Pembrolizumab in Participants With Hepatocellular CarcinomaCompletedNCT03006926Phase 1Results posted
• A Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced DiseaseCompletedNCT02915783Phase 2Results posted
• Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular CarcinomaCompletedNCT02834780Phase 1Results posted
• A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)TerminatedNCT02657369Phase 2Results posted
• Study of Lenvatinib in Combination With Everolimus in Participants With Unresectable Advanced or Metastatic Renal Cell Carcinoma (RCC)CompletedNCT02454478Phase 1Results posted
• A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular CarcinomaCompletedNCT01761266Phase 3Results posted
• E7050 in Combination With Cetuximab Versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and NeckCompletedNCT01332266Phase 1/2Results posted
• E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Participants With Hepatocellular CarcinomaCompletedNCT01271504Phase 1/2Results posted
• Study of Lenvatinib (E7080) in Participants With Advanced Hepatocellular Carcinoma (HCC)CompletedNCT00946153Phase 1/2Results posted
• A Study of Lenvatinib in Combination With Pembrolizumab in Korean PatientsCompletedNCT05375136
• A Study of Lenvima (Lenvatinib) in Korean Unresectable Hepatocellular Carcinoma (uHCC) ParticipantsCompletedNCT05225207
• A Study to Evaluate the Safety and Tolerability of Lenvatinib in Participants With Advanced or Unresectable Hepatocellular CarcinomaCompletedNCT04763408
• A Study to Assess the Safety and Efficacy of Lenvatinib as First-line Treatment in Participants With Unresectable HCCCompletedNCT04297254Phase 4
• A Study of Overall Survival in Participants With Unresectable Hepatocellular CarcinomaCompletedNCT04008082
• A Post-marketing Observational Study on Risk Factors for Hepatic Encephalopathy in Participants With Unresectable Hepatocellular CarcinomaCompletedNCT03663114
• Pharmacokinetic Study of E7080/Lenvatinib in Chinese Patients With Unresectable Hepatocellular Carcinoma (HCC)CompletedNCT02953743Phase 1
• Post-marketing Surveillance of DC Bead in Patients With Hepatocellular CarcinomaCompletedNCT02269995
• A Phase II/III Clinical Study on Inhibitory Effects of E0167 on Recurrence of Hepatocellular CarcinomaTerminatedNCT00165633Phase 2/3
• A Safety, Tolerability and Efficacy Study of E7070 in Patients With Renal Cell CarcinomaCompletedNCT00059735Phase 2